The PBS ending a 'topsy turvy' decade as two programs

December 16, 2019 Latest News News of the Day

This is a preview of subscriber content

Subscribe now to continue reading.

The BioPharmaDispatch analysis of the recently released annual PBS Expenditure and Prescriptions report has confirmed the challenge of assessing the scheme based on spending growth but confirms how it has effectively transformed into two programs. …

Subscribe now to continue reading.

Latest Video

Georgia Forrest

FDA approved new cancer therapy and delivers patient access in just 44 days
March 3, 2026 - Latest News
Genetic breakthrough brings new hope for Australians living with multiple sclerosis
March 3, 2026 - Latest News
New report says faster and fairer access to medicines within reach for New Zealand
March 3, 2026 - Latest News
Australia counts the massive cost of obesity as new report warns of a growing economic crisis
March 2, 2026 - Latest News
Pharma teams surge past $225,000 in 2026 Rare Cancers Australia Kosi Challenge
March 3, 2026 - Latest News

The PBS ending a 'topsy turvy' decade as two programs

This is a preview of subscriber content

Latest Video

Most Read

FDA approved new cancer therapy and delivers patient access in just 44 days

Genetic breakthrough brings new hope for Australians living with multiple sclerosis

New report says faster and fairer access to medicines within reach for New Zealand

Australia counts the massive cost of obesity as new report warns of a growing economic crisis

Pharma teams surge past $225,000 in 2026 Rare Cancers Australia Kosi Challenge

New Stories

Setting the standard for safe and accountable virtual healthcare in Australia

A system built for a past is struggling to meet the challenge of today, let alone the future

Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates

AdAlta strengthens clinical push for breakthrough solid cancer therapy

Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment

PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise

Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen

Sign In

The PBS ending a 'topsy turvy' decade as two programs

This is a preview of subscriber content

Latest Video

Most Read

FDA approved new cancer therapy and delivers patient access in just 44 days

Genetic breakthrough brings new hope for Australians living with multiple sclerosis

New report says faster and fairer access to medicines within reach for New Zealand

Australia counts the massive cost of obesity as new report warns of a growing economic crisis

Pharma teams surge past $225,000 in 2026 Rare Cancers Australia Kosi Challenge

Follow Us

New Stories

Setting the standard for safe and accountable virtual healthcare in Australia

A system built for a past is struggling to meet the challenge of today, let alone the future

Firebrick Pharma targets breakout year in 2026 as Nasodine expansion accelerates

AdAlta strengthens clinical push for breakthrough solid cancer therapy

Island Pharmaceuticals deepens US biodefence ties to advance Marburg treatment

PYC Therapeutics secures strong backing as retail offer adds $47 million to capital raise

Alterity strengthens clinical leadership with appointment of neurologist Daniel Claassen